In the phase II trials for NSCLC patients with HER2 mutations, sub-group analyses revealed comparable outcomes in patients with CNS metastasis who were treated with trastuzumab deruxtecan or pyrotinib. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.